Mar 15, 2023
Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278).
Feb 27, 2023
Recently, CGeneTech (Suzhou) Co., Ltd. (CGeneTech) submitted the DPP-4 inhibitor Sitagliptin, for the treatment of type 2 diabetes, to the National Medical Products Administration (NMPA) for approval. Shanghai Medicilon Inc.